pyrazines has been researched along with osimertinib in 8 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 8 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Früh, M; Peters, S; Schmid, S | 1 |
| Ahn, MJ; Cantarini, M; Cho, BC; Frewer, P; Han, JY; Kim, SW; Kowalski, D; Lee, JS; Mellemgaard, A; Orlov, S; Ottesen, L; Ou, X; Oxnard, G; Sequist, LV; Su, WC; Verheijen, RB; Yang, JC; Yu, H | 1 |
| Ahn, MJ; Frigault, MM; Ghiorghiu, D; Goto, K; Horn, L; Kim, SW; Mann, H; Ohe, Y; Oxnard, GR; Ramalingam, SS; Saka, H; Thress, KS; Vishwanathan, K; Yang, JC; Yu, H | 1 |
| Arai, S; Atagi, S; Fukuda, K; Han, X; Hanayama, R; Ishimura, A; Kaira, K; Kita, K; Matsumoto, I; Matsumoto, K; Nishiyama, A; Ohtsubo, K; Suzuki, T; Takayama, K; Takeuchi, S; Taniguchi, H; Taniguchi, Y; Tanimoto, A; Terashima, M; Uehara, H; Wang, R; Wang, W; Yamada, T; Yamano, T; Yamashita, K; Yano, S; Yoshimura, A | 1 |
| Ahmed, GF; Hayama, M; Hida, T; Hirashima, T; Kurata, T; Mellemgaard, A; Ohe, Y; Ou, X; Oxnard, GR; Saka, H; Sugibayashi, K; Verheijen, RB; Yoh, K | 1 |
| Chen, DS; Fang, Y; Gao, W; Gu, Y; Huang, R; Ma, P; Shu, Y; Wu, X; Zhang, HW | 1 |
| Abreu, RF; Carraro, DM; Cavalher, FP; Corassa, M; Costa, FD; de Lima, VCC; Freitas, HC; Oliveira, TB; Silva, TN; Torrezan, GT | 1 |
3 trial(s) available for pyrazines and osimertinib
| Article | Year |
|---|---|
Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study.
Topics: Acrylamides; Adult; Aged; Aged, 80 and over; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Double-Blind Method; Drug Resistance, Neoplasm; ErbB Receptors; Female; Follow-Up Studies; Gene Amplification; Humans; Lung Neoplasms; Male; Middle Aged; Mutation; Neoplasm Metastasis; Neoplasm Recurrence, Local; Prognosis; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-met; Pyrazines; Salvage Therapy; Survival Rate; Triazines | 2020 |
TATTON: a multi-arm, phase Ib trial of osimertinib combined with selumetinib, savolitinib, or durvalumab in EGFR-mutant lung cancer.
Topics: Acrylamides; Aniline Compounds; Antibodies, Monoclonal; Antineoplastic Combined Chemotherapy Protocols; Benzimidazoles; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazines; Triazines | 2020 |
Savolitinib ± Osimertinib in Japanese Patients with Advanced Solid Malignancies or EGFRm NSCLC: Ph1b TATTON Part C.
Topics: Acrylamides; Aged; Aniline Compounds; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Non-Small-Cell Lung; Humans; Japan; Lung Neoplasms; Male; Middle Aged; Pyrazines; Triazines | 2021 |
5 other study(ies) available for pyrazines and osimertinib
| Article | Year |
|---|---|
Targeting MET in EGFR resistance in non-small-cell lung cancer-ready for daily practice?
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazines; Triazines | 2020 |
Non-Small Cell Lung Cancer Responds to Osimertinib plus Savolitinib.
Topics: Acrylamides; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Lung Neoplasms; Mutation; Protein Kinase Inhibitors; Pyrazines; Triazines | 2020 |
Transient IGF-1R inhibition combined with osimertinib eradicates AXL-low expressing EGFR mutated lung cancer.
Topics: Acrylamides; Aged, 80 and over; Aniline Compounds; Animals; Axl Receptor Tyrosine Kinase; Carcinoma, Non-Small-Cell Lung; Cell Line, Tumor; Cell Survival; ErbB Receptors; Gene Expression Regulation, Neoplastic; Hepatocyte Nuclear Factor 3-alpha; Humans; Imidazoles; Lung Neoplasms; Male; Mice; Models, Biological; Mutation; Phosphorylation; Proto-Oncogene Proteins; Pyrazines; Receptor Protein-Tyrosine Kinases; Receptor, IGF Type 1; RNA, Messenger; Up-Regulation | 2020 |
Savolitinib monotherapy exerted significant benefit in a non-small cell lung cancer patient with osimertinib resistance harboring primary EGFR L858R mutation and MET amplification: a case report.
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; Bevacizumab; Carcinoma, Non-Small-Cell Lung; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrazines; Pyrimidines; Triazines | 2022 |
Rhabdomyosarcomatous Transformation as a Mechanism of Resistance to Osimertinib and Savolitinib in EGFR-Mutant Lung Adenocarcinoma With
Topics: Acrylamides; Adenocarcinoma of Lung; Aniline Compounds; ErbB Receptors; Humans; Indoles; Lung Neoplasms; Pyrazines; Pyrimidines; Triazines | 2022 |